National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
This study is a multicenter, open-label, observational, postmarketing surveillance study that
 will collect information on the use of Genentech GH preparations to treat GH-deficient
 subjects with optimal GH dosing during puberty.
Inclusion Criteria:

 -  Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or
 greater)

 -  Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater

 -  Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk

 -  Ability to keep follow-up appointments throughout the study

 -  Willingness to remain on therapy until epiphyseal closure is achieved

 -  Prior enrollment in NCGS Core Study 85-036

 Exclusion Criteria:

 -  Treatment with non-Genentech GH preparation

 -  Closed epiphyses

 -  Active neoplasia

 -  Treatment with insulin for diabetes